Modality: targeted clearance / protein degradation; currently in discovery.
IPTarget undisclosed
R&DDiscovery stage
03THERAPEUTIC R&D
TARGETED CLEARANCE · PROTEIN DEGRADATION
Targeted clearance
and protein degradation
Podigy is exploring targeted-clearance and protein-degradation candidates for kidney diseases, supported by molecular design, activity assessment and in-vivo validation capabilities.
DiscoveryCurrently in candidate discovery and validation
Internal assays support candidate screening, activity assessment and developability decisions.
Specific targets, ligands, receptors, molecular structures and detailed mechanisms are undisclosed.
R&D boundary: these programs remain in discovery and validation. Targets, molecular structures, experimental data and mechanisms will be disclosed progressively in line with intellectual-property and partnership considerations. No product in this program is approved for clinical use.